{"id":"W2157049259","doi":"10.3747/co.21.1661","title":"Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Cetuximab; Medicine; Vemurafenib; KRAS; Colorectal cancer; Trametinib; Cancer research; Dabrafenib; Targeted therapy; Oncology; Epidermal growth factor receptor; Kinase; Internal medicine; Refractory (planetary science); EGFR inhibitors; Cancer; Melanoma; MAPK/ERK pathway; Metastatic melanoma; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004531767,0.0002229815,0.000804799,0.0002563523,0.00008870414,0.00001491731,0.0001384491,0.0001347759,0.001438483],"category_scores_gemma":[0.000206491,0.0001907088,0.0001996959,0.0003064401,0.0002917388,0.0001628105,0.00005427971,0.0003828211,0.0000123763],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009235236,"about_ca_system_score_gemma":0.0009909407,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002036115,"about_ca_topic_score_gemma":0.00002026916,"domain_scores_codex":[0.9980385,0.0002952093,0.0004086462,0.000374265,0.0003944475,0.0004889869],"domain_scores_gemma":[0.998006,0.0005965131,0.0002919897,0.0002935744,0.0006471954,0.0001646777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002497923,0.001850643,0.006337276,0.0002138951,0.0001735051,0.000006767829,0.0007805626,0.000004523988,0.8002275,0.00005651037,0.0002967491,0.1875541],"study_design_scores_gemma":[0.04780247,0.01553286,0.1913507,0.0001698313,0.0004223966,0.000131454,0.0006895169,0.08642077,0.6188834,0.0007037441,0.03721534,0.0006775235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932778,0.001327656,0.0008710845,0.0004075068,0.000926669,0.002881379,0.00003847807,0.0000388278,0.0002306352],"genre_scores_gemma":[0.9984297,0.0002900453,0.0005665523,0.00004955715,0.0001639402,0.0002828823,0.00006024382,0.0000451475,0.0001119909],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1868766,"threshold_uncertainty_score":0.9994743,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1687028635476653,"score_gpt":0.4394991136432984,"score_spread":0.270796250095633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}